No Data
No Data
Express News | Chardan Capital Maintains Buy on Notable Labs, Lowers Price Target to $5
Buy Rating Affirmed for Notable Labs Amid Promising Drug Program and Robust PPMP Platform
Notable Labs | 10-Q: Quarterly report
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society...
Tivic Health, RAPT Therapeutics, Notable Labs Among Healthcare Movers
No Data